Literature DB >> 24402820

Computational evaluation of new homologous down regulators of Translationally Controlled Tumor Protein (TCTP) targeted for tumor reversion.

Anuraj Nayarisseri1, Mukesh Yadav, Rohan Wishard.   

Abstract

The Translationally Controlled Tumor Protein (TCTP) has been investigated for tumor reversion and is a target of cancer therapy. Down regulators which suppress the expression of TCTP can trigger the process of tumor reversion leading to the transformation of tumor cells into revertant cells. The present investigation is a novel protein-protein docking approach to target TCTP by a set of proteins similar to the protein: sorting nexin 6 (SNX6) which is an established down regulator of TCTP. The established down regulator along with its set of most similar proteins were modeled using the PYTHON based software - MODELLER v9.9, followed by structure validation using the Procheck Package. Further TCTP was docked with its established and prospective down regulators using the flexible docking protocol suite HADDOCK. The results were evaluated and ranked according to the RMSD values of the complex and the HADDOCK score, which is a weighted sum of van der Waal's energy, electrostatic energy, restraints violation energy and desolvation energy. Results concluded the protein sorting nexin 6 of Mus musculus to be a better down regulator of TCTP, as compared to the suggested down regulator (Homo sapiens snx6).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24402820     DOI: 10.1007/s12539-013-0183-8

Source DB:  PubMed          Journal:  Interdiscip Sci        ISSN: 1867-1462            Impact factor:   2.233


  7 in total

1.  Alkyloxy carbonyl modified hexapeptides as a high affinity compounds for Wnt5A protein in the treatment of psoriasis.

Authors:  Ankit Kelotra; Sadashiv M Gokhale; Seema Kelotra; Vaidehi Mukadam; Komal Nagwanshi; Srinivas Bandaru; Anuraj Nayarisseri; Anil Bidwai
Journal:  Bioinformation       Date:  2014-12-31

2.  Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis.

Authors:  Divya Jain; Trishang Udhwani; Shreshtha Sharma; Aishwarya Gandhe; Palugulla Bhaskar Reddy; Anuraj Nayarisseri; Sanjeev Kumar Singh
Journal:  Bioinformation       Date:  2019-02-28

3.  Design of PD-L1 inhibitors for lung cancer.

Authors:  Trishang Udhwani; Sourav Mukherjee; Khushboo Sharma; Jajoriya Sweta; Natasha Khandekar; Anuraj Nayarisseri; Sanjeev Kumar Singh
Journal:  Bioinformation       Date:  2019-02-28

4.  FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia.

Authors:  Padmini Gokhale; Aashish Pratap Singh Chauhan; Anushka Arora; Natasha Khandekar; Anuraj Nayarisseri; Sanjeev Kumar Singh
Journal:  Bioinformation       Date:  2019-02-28

5.  Virtual Screening of IL-6 Inhibitors for Idiopathic Arthritis.

Authors:  Palak Shukla; Ravina Khandelwal; Diksha Sharma; Anindya Dhar; Anuraj Nayarisseri; Sanjeev Kumar Singh
Journal:  Bioinformation       Date:  2019-02-28

6.  Structure based virtual screening of ligands to identify cysteinyl leukotriene receptor 1 antagonist.

Authors:  Srinivas Bandaru; Vijaya Kumar Marri; Priyadarshani Kasera; Purnima Kovuri; Amandeep Girdhar; Deepti Raj Mittal; Sabeen Ikram; Ravi Gv; Anuraj Nayarisseri
Journal:  Bioinformation       Date:  2014-10-30

7.  Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition.

Authors:  Chanda Sinha; Anuradha Nischal; Kamlesh K Pant; Srinivas Bandaru; Anuraj Nayarisseri; Sanjay Khattri
Journal:  Bioinformation       Date:  2014-10-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.